Global Thyroid Eye Disease (TED) Market: Major Trends Reshaping the Future of the Industry

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Thyroid Eye Disease (TED) Industry Market Size Be by 2025?
The overall valuation for the thyroid eye disease sector has experienced a robust upward trajectory recently, projected to expand from a figure of $2.15 billion in 2024 to reach $2.29 billion by the subsequent year, illustrating a compound annual growth rate (CAGR) of 6.7%. This expansion observed during the past period is fundamentally linked to a confluence of factors, including the increasing incidence of thyroid ailments, an intensified dedication toward care models centered around the individual patient, escalating consumer interest in aesthetic interventions, a higher frequency of the condition being diagnosed, alongside a broader availability of therapeutic modalities for TED.

What's the Long-Term Growth Forecast for the Thyroid Eye Disease (TED) Market Size Through 2029?
Anticipating a robust expansion, the market for thyroid eye disease (ted) is projected to achieve a valuation of $2.94 billion by 2029, underpinned by a compound annual growth rate (CAGR) of 6.4% across the forecasted duration, with this upward trajectory fueled by the rising frequency of Graves' disease, augmented financial backing across relevant sectors, greater spending on healare services, broader adoption of thyroid hormone replacement treatments, and the escalation in overall thyroid disease occurrences; concurrently, significant shifts within this period are expected to manifest through sophisticated technological progress, heightened research and development efforts, the introduction of innovative pharmaceuticals, improvements in available therapeutic modalities, and the emergence of refined surgical procedures.

View the full report here:
https://www.thebusinessresearchcompany.com/report/thyroid-eye-disease-ted-global-market-report

What Are the Key Growth Drivers Fueling the Thyroid Eye Disease (TED) Market Expansion?
An upward trajectory in thyroid ailments is anticipated to be the catalyst for the expansion of the thyroid eye disease (TED) market in the near future. Thyroid disorders encompass medical issues impacting the thyroid gland's operation, resulting in hormonal production imbalances that manifest as conditions like hyperthyroidism, hypothyroidism, goiter, and thyroid eye disease itself. The escalation of thyroid disorders is attributed to several elements, including heightened iodine consumption, autoimmune predispositions, inherited factors, and enhanced detection stemming from better diagnostic capabilities. As a frequent and severe sequela of Graves' disease, Thyroid Eye Disease (TED) adds to the overall increase in thyroid disorder instances, thereby augmenting both the prevalence and recognition of thyroid-related health concerns. To illustrate this, data from the Canadian Cancer Society, a Canadian non-profit community organization, indicated in May 2024 that Canada is projected to see an estimated 6,600 new thyroid cancer diagnoses in 2024, alongside roughly 280 anticipated deaths. Consequently, the proliferation of thyroid disorders is directly fueling the expansion of the thyroid eye disease (TED) market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21300&type=smp

What Are the Key Trends Driving Thyroid Eye Disease (TED) Market Growth?
A key focus among the foremost enterprises within the thyroid eye disease (TED) sector involves pioneering novel therapeutics, particularly monoclonal antibody treatments, aiming to craft superior, precisely targeted interventions that mitigate inflammatory responses, alleviate proptosis, and elevate general patient results. These laboratory-engineered antibody treatments function by emulating the body's natural immune defenses to zero in on and deactivate particular disease agents or aberrant cells. Illustratively, in the month of September in 2024, the American biotechnology firm Amgen Inc. disclosed that Japan's regulatory body, the Ministry of Health, Labour and Welfare (MHLW), granted authorization for TEPEZZA (teprotumumab) in addressing active TED, which represents an uncommon autoimmune ailment carrying the risk of sight loss. As the sole therapy specifically sanctioned by the FDA for this indication, this medication delivers a focused approach, aiding in the reduction of swelling, inflammation, and the various limiting symptoms linked to the condition. This regulatory milestone carries significant weight for the Japanese patient population, furnishing them with a newly available, potent avenue for managing TED, a rare and escalating ailment characterized by severe eye protrusion, visual impairment, and ocular discomfort.

How Is the Thyroid Eye Disease (TED) Market Segmented?
The thyroid eye disease (ted)market covered in this report is segmented -

1) By Treatment Type: Medical; Surgical; Combination Of Medical And Surgical
2) By Disease Severity: Mild; Moderate; Severe
3) By Drug Type: Biologics; Small Molecules; Others Drug Type
4) By Route Of Administration: Oral; Intravenous; Subcutaneous
5) By End User: Hospitals; Clinics; Other End Users

Subsegments:
1) By Medical: Corticosteroids; Teprotumumab; Antithyroid Medications; Other Medical Treatments
2) By Surgical: Orbital Decompression Surgery; Eyelid Surgery; Strabismus Surgery
3) By Combination Of Medical and Surgical: Combination of Corticosteroids and Orbital Decompression; Combination of Teprotumumab and Eyelid Surgery; Other Combined Approaches

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=21300&type=smp

Which Companies Are Leading the Charge in Thyroid Eye Disease (TED) Market Innovation?
Major companies operating in the thyroid eye disease (TED) market are Hoffmann-La Roche AG, Amgen Inc., Genentech Inc., Horizon Therapeutics plc, Pierre Fabre S.A., Innovent Biologics Inc., ACELYRIN Inc., Soleo Health, Zai Lab Limited, HanAll Biopharma Co. Ltd., Tourmaline Bio Inc., Zenas BioPharma Inc., Immunovant Inc., Verana Health, Harbour BioMed (Guangzhou) Co. Ltd., Sling Therapeutics Inc., Crinetics Pharmaceuticals Inc., Lassen Therapeutics Inc., Viridian Therapeutics Inc., Minghui Pharmaceutical Inc.

Which Regions Are Leading the Global Thyroid Eye Disease (TED) Market in Revenue?
North America was the largest region in the thyroid eye disease (TED) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the thyroid eye disease (TED) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21300

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.